secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-07-13T23:59:59+00:00
Accession:  0001683168-22-004911
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health completes Phase I SAD trial for concussion drug PRV-002; moving to MAD phase
--------------------------------------------------------------------------------

- Phase I Single Ascending Dosing (SAD) completed with three cohorts; drug PRV-002 safe and well tolerated, no severe adverse events.
- Cohort III (8 healthy volunteers) cleared; Safety Review Committee unanimously approved start of Multiple Ascending Dosing (MAD) Cohort I.
- Intranasal delivery showed low blood levels of PRV-002, supporting targeted brain delivery hypothesis.
- Company planning FDA meeting to present Phase I data; Phase II trial sites and study design under development.
- Global concussion treatment market valued at $6.9B (2020), forecast to reach $8.9B by 2027 (Grandview Research).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822004911/0001683168-22-004911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822004911/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-004911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer